Loading stock data…
EW
$87.54+1.69 (+1.97%)
After Hours$87.05-0.49 (-0.56%)· Last close Jun 9
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Edwards Lifesciences Corporation in the Healthcare sector is trading at $87.54. Wall Street consensus targets $96.92 (26 analysts), implying a +10.7% move over the next 12 months. The stock is currently near its 52-week high of $89.48, remaining 7.0% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +10.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$87.54
Potential Downside
0%
Whystock Fair Value$87.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus26 analysts
Buy
Mean target$96.92+10.7%
Range$84.00 – $110.00
Fundamentals
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive re...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.58%
Volume
Today's trading volume
2.73M
Recent News
Possible Bearish Signals With Edwards Lifesciences Insiders Disposing Stock
Over the past year, many Edwards Lifesciences Corporation ( NYSE:EW ) insiders sold a significant stake in the company...
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Edwards Lifesciences Stock Underperforming the Nasdaq?
Despite trailing the broader Nasdaq Composite over the last 12 months, Edwards Lifesciences continues to earn strong support from analysts.
Undervalued Asian Small Caps With Insider Action For June 2026
As Asian markets navigate a complex landscape shaped by geopolitical developments and regulatory shifts, small-cap stocks in the region present intriguing opportunities for investors seeking growth potential amid broader economic uncertainties. With the backdrop of fluctuating industrial profits in China and Japan's energy-dependent economy responding to Middle East tensions, identifying small-cap companies with strong fundamentals and insider engagement can be key to uncovering value in this...
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.